Keywords: Novartis, Job cuts, Restructuring, Savings, Diovan, Rasilez, Tekturna

Novartis cuts jobs, takes $1.22 billion charges

Article | 13 January 2012

Print This

In anticipation of the blockbuster antihypertensive Diovan’s (valsartan) patent expiration and an expected reduction in demand for Rasilez/ ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in